SCHEDULE: Highbridge Capital Discloses 5.2% Stake in Inmune Bio

Highbridge Capital Management, LLC reported a 5.2% beneficial ownership stake in Inmune Bio, Inc., primarily through warrants.

Summary

• Highbridge Capital Management, LLC, an investment adviser, reported beneficial ownership of 1,454,400 shares of Inmune Bio, Inc. Common Stock.
• This represents 5.2% of Inmune Bio's outstanding Common Stock.
• The reported shares are issuable upon the exercise of warrants directly held by the Highbridge Funds.
• The percentage is calculated based on an aggregate of 26,585,258 shares of Common Stock outstanding as of June 30, 2025, as reported in Inmune Bio's Prospectus filed pursuant to Rule 424(b)(5).
• This is an Amendment No. 1 to a previous Schedule 13G filing, indicating an update to Highbridge's beneficial ownership position.

Sentiment

Score: 7

Explanation: A significant stake by a reputable investment firm like Highbridge Capital Management is generally a positive signal, indicating confidence in the company's value or future prospects, even if it's a passive investment.

Positives

• Highbridge Capital Management, a significant investment adviser, holds a notable stake, potentially signaling confidence in Inmune Bio's value or future prospects.
• The ownership is primarily through warrants, which can suggest a strategic or long-term investment interest.

Future Outlook

Not applicable as this filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing indicates a significant investment by a major capital management firm in Inmune Bio, Inc. Such investments can signal investor confidence in the company's prospects within the competitive biotechnology sector, which often relies on substantial capital for research and development and can benefit from institutional backing.

Comparison to Industry Standards

• Not applicable. This filing is a disclosure of beneficial ownership by an investment firm, not a performance report by the issuer. Therefore, there are no comparable company results or industry benchmarks to assess within this document.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder may increase investor confidence and potentially influence stock perception.
• Company: Highbridge Capital Management's stake could provide a stable shareholder base or potential strategic support.

Next Steps

• No specific future actions or milestones are mentioned in this beneficial ownership report.

Key Dates

Keywords

Inmune Bio, Highbridge Capital Management, SEC filing, Schedule 13G, beneficial ownership, common stock, warrants, investment adviser, biotechnology